{
  "id": "5e5e508b1af46fc13000000c",
  "type": "factoid",
  "question": "What does Retapamulin treat?",
  "ideal_answer": "Retapamulin  is a small molecule covalently binding and inhibiting the bacterium Staphylococcus aureus (MRSA).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20066388",
    "http://www.ncbi.nlm.nih.gov/pubmed/19344241",
    "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
    "http://www.ncbi.nlm.nih.gov/pubmed/16940066",
    "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
    "http://www.ncbi.nlm.nih.gov/pubmed/18416589",
    "http://www.ncbi.nlm.nih.gov/pubmed/23793314",
    "http://www.ncbi.nlm.nih.gov/pubmed/23837927",
    "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
    "http://www.ncbi.nlm.nih.gov/pubmed/24935401",
    "http://www.ncbi.nlm.nih.gov/pubmed/28874907",
    "http://www.ncbi.nlm.nih.gov/pubmed/25396674",
    "http://www.ncbi.nlm.nih.gov/pubmed/18725451",
    "http://www.ncbi.nlm.nih.gov/pubmed/16957433",
    "http://www.ncbi.nlm.nih.gov/pubmed/21191403",
    "http://www.ncbi.nlm.nih.gov/pubmed/18973410",
    "http://www.ncbi.nlm.nih.gov/pubmed/18041900",
    "http://www.ncbi.nlm.nih.gov/pubmed/28491950",
    "http://www.ncbi.nlm.nih.gov/pubmed/25250996",
    "http://www.ncbi.nlm.nih.gov/pubmed/18341664",
    "http://www.ncbi.nlm.nih.gov/pubmed/20941943"
  ],
  "snippets": [
    {
      "text": " the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant S. aureus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28491950",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To determine clinical and bacteriological efficacy of retapamulin ointment 1% in treatment of patients with cutaneous bacterial infections caused by methicillin-resistant S. aureus (MRSA) and other bacteria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28491950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Fusidic acid, mupirocin, and retapamulin cover methicillin-susceptible S. aureus and streptococcal infections. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25250996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25250996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25396674",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " To evaluate the clinical and bacteriological efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of patients with secondarily infected traumatic lesions (SITLs; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25396674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a semisynthetic pleuromutilin derivative being developed as a topical antibiotic for treating bacterial infections of the skin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin appears to be a much needed antimicrobial option for treating the AD population due to their common carriage of bacterial pathogens and frequency of infectious complications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20066388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341664",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20066388",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In vitro, retapamulin is highly potent against S. aureus and has a lower propensity to develop resistance than mupirocin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20941943",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(twice-daily) dosing of retapamulin is highly effective against impetigo due to methicillin- susceptible S. aureus and Streptococcus pyogenes and may play an important role in limiting the development of resistance against systemic agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20941943",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2007, retapamulin was the first agent for human use approved in the pleuromutilin class of antibacterials in the United States (U.S.), and is the first topical antibacterial indicated to treat impetigo in over 20 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20941943",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20941943",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "tion. Retapamulin 1% ointment is a unique topical antibiotic formulation that may be a suitable option for the treatment of clinically infected",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e, treatment of a USA300 MRSA skin infection with retapamulin ointment resulted in up to 85-fold reduction in bacterial burden and a 53% decrease in infection-induced inflammation. In contrast, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21191403",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dic acid and mupirocin treatment for 3 days reduced the bacterial loads by 2.5, 2.9 and 2.0 log(10) CFU, respectively, and treatment for 6 days by 5.0, 4.2 and 5.1 log(10) CFU, respectively, compared with non-treated controls (P < 0.001). Systemic treatment with line",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23837927",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding meticillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months. In the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18416589",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding methicillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months. In the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18973410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin, the first pleuromutilin antimicrobial agent approved for the topical treatment of skin infections in humans, was tested against 987 clinical isolates representing 30 species and/or resistance groups. MIC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725451",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Retapamulin is a novel, topical antibacterial of the pleuromutilin class in development for the treatment of secondarily infected traumatic lesions ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16957433",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Further, the clinical efficacy and safety profile of retapamulin was comparable to that of commonly used oral and topical antibiotics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As a 1% ointment, retapamulin has been approved in the United States for the treatment of impetigo and in Europe for the shortterm treatment of impetigo and infected small lacerations, abrasions and sutured wounds.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is the first agent in the new pleuromutilin class of antibacterials to become commercially available for clinical use in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical efficacy trials involving pediatric and adult patients who received retapamulin twice daily for five days, retapamulin was highly effective in the treatment of impetigo, secondarily infected traumatic lesions and secondarily infected dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In preclinical studies, retapamulin demonstrated pronounced in vitro activity against staphylococcal, streptococcal and anaerobic Gram-positive clinical isolates associated with skin and skin structure infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin acts as a potent inhibitor of bacterial protein synthesis and has a unique mode of antibiotic action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Retapamulin is a novel, topical antibacterial of the pleuromutilin class in development for the treatment of secondarily infected traumatic lesion",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16957433",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344241",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Retapamulin, a topical pleuromutilin that selectively inhibits bacterial protein synthesis, is approved for treatment of impetigo and secondarily infected traumatic lesions in adults and in children older than 9 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24935401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children and has been recently made available in the Indian market.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23793314",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18041900",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "flammation. Retapamulin 1% ointment is a unique topical antibiotic formulation that may be a suitable option for the treatment of clinically ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding methicillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18973410",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "bacterial infections"
}